Asceneuron
Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.
Asceneuron is active in the biotechnology, health care, therapeutics space based in Europe, Middle East, and Africa (EMEA), founded in 2012.
Its activity falls under biotechnology, health care, therapeutics; the profile below is assembled from public directory data.
The company is recorded as being based in Europe, Middle East, and Africa (EMEA).
Its current recorded stage is Series_C.
The company reports a headcount in the c_00011_00050 range.
Total disclosed funding stands at about $130.8M.
| Sector | Biotechnology, Health Care, Therapeutics |
|---|---|
| Headquarters | Europe, Middle East, and Africa (EMEA) |
| Founded | 2012 |
| Employees | c_00011_00050 |
| Stage | series_c |
| Total funding | $130,846,236 |
Website: asceneuron.com
Sign in to view the contact information we hold for Asceneuron.
Create a free account
Create a free account